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Background:  Several  clinical  trials  showed  inconsistent  results  of  the  effect  of polyunsaturated  fatty  acids
(PUFA)  on  the  incidence  of  post-operative  atrial ﬁbrillation  (POAF).  The  aim  of  this  meta-analysis  is to
investigate  the effect  of  PUFA  on  the  incidence  of  POAF  in patients  undergoing  cardiac  surgery.
Methods and  results:  PUBMED,  EMBASE,  Cochrane  Library,  and  Google  Scholar  databases  were  searched
for  randomized  controlled  trials.  Statistical  heterogeneity  was  assessed  using  I2 statistic  and  Cochran’s  Q
statistic.  The  effect  of  PUFA  on  the  incidence  of  POAF  was presented  as risk  ratio  (RR)  with  95%  conﬁdence
intervals  (CIs)  using  a ﬁxed  effect  model  or random  effect  model  depending  on statistical  heterogeneity.
Subgroup  analyses  were  conducted  based  on  the  baseline  characteristics  of  patients,  types  of surgery,
the  ratio  of  eicosapentaenoic  acid  (EPA)/docosahexaenoic  acid  (DHA),  and  the  quality  of  the  studies.
Eight  trials  with  2687  patients  were  included  in  the  analysis.  Treatment  with  PUFA  had  no  effect  on  the
incidence  of  POAF  in  patients  undergoing  cardiac  surgery  compared  to  placebo  [RR 0.86;  95% CI  0.71–1.04,
p  =  0.110].  Subgroup  analyses  showed  the  quality  of the  studies,  the  ratio  of EPA/DHA,  accompanied  with
diabetes  might  impact  the  effect  of PUFA  on  POAF.  No  evidence  of  publication  bias  was  detected.
Conclusions: The  present  analysis  suggests  that  treatment  with  PUFA  preoperatively  has  no  effect  on  the
incidence  of POAF  in patients  undergoing  open  heart surgery.  However,  patients  with  diabetes  might  get
beneﬁts  from  the  treatment  with  PUFA  preoperatively.
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Atrial ﬁbrillation (AF) is the most common arrhythmia after car-
iac surgery. Despite ongoing efforts to prevent the occurrence, the
ncidence of post-operative atrial ﬁbrillation (POAF) ranges from
0% to 70% [1]. In addition, POAF is associated with prolonged
ospitalization, and increased costs, morbidity, and mortality [2].
urthermore, classic anti-arrhythmic drugs have not been effective
n preventing POAF [3]. Therefore, we should try our best to inves-
igate new strategies to prevent the occurrence of POAF in patients
ndergoing open heart surgery.
Intake of ﬁsh or ﬁsh oil appears to reduce risk of coronary
eath, perhaps through reduction of primary ventricular arrhyth-
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mias [4]. Animal experiments showed that polyunsaturated fatty
acids (PUFA) suppressed congestive heart failure-induced atrial
structural remodeling and AF promotion [5]. A clinical trial also
showed beneﬁcial effect of PUFA on prevention of POAF in patients
undergoing coronary artery bypass grafting (CABG) [6]. However,
some other trials of PUFA reported conﬂicting results on its efﬁcacy
in preventing POAF [7–13]. Since earlier meta-analyses estimating
the effect of PUFA on POAF in patients undergoing cardiac surgery
[14], the results of four new trials have been reported. These stud-
ies increased almost ﬁve times the number of patients enrolled
in randomized trials. So we  performed a new meta-analysis of
randomized controlled trials to estimate the effect of PUFA on pre-
venting POAF in patients undergoing cardiac surgery.
Materials and methods
Literature  searchA  literature search was  performed on the PUBMED, EMBASE,
Cochrane Library, and Google Scholar databases to identify all the
studies that reported the effect of PUFA on the prevention of POAF
vier Ltd. All rights reserved.
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n patients undergoing cardiac surgery. The following medical
ubject headings were used: cardiac surgery, atrial ﬁbrillation, and
olyunsaturated fatty acids (or ﬁsh oil). Searches were also per-
ormed under the headings of coronary artery bypass graft, cardio-
horacic surgery, and polyunsaturated fatty acids. For all relevant
ublications, the records retrieved with the “related articles”
ink in PUBMED were reviewed; reference lists were checked for
ther relevant studies. The ﬁnal literature search was  ﬁnished on
ecember 31st, 2012 and all the searches were limited to English
anguage publications. The major inclusion criteria were: (1) the
esign was a randomized controlled clinical trial; (2) the patients
n the trial underwent cardiac surgery; (3) the main outcomes
ncluded the incidence of POAF. The major reasons for exclusion
f studies were: (1) overlapping data; (2) patients aged < 18 years
ld; (3) history of AF or Class I/III anti-arrhythmic medications; and
4) data published in the form of abstracts without peer-reviewed
ublication of manuscripts.
ata  collection and quality assessment
Two investigators (B. Zhang and Y. Zhen) independently
eviewed all potentially eligible studies using predeﬁned eligibility
riteria and collected data from the included trials. Any discrep-
ncy was resolved by consensus. Baseline characteristics of patients
ere extracted as well as data about each trial’s intervention and
utcomes assessed. Quality assessments were evaluated with Jadad
uality scale, which enables the adequacy of randomization, blind-
ng, and the handling of withdrawals and dropouts, and a numerical
core between 0 and 5 was assigned as a measure of study design
15].
tatistical analyses
Statistical analyses were performed using STATA 11.0 (Stata-
orp LP, College Station, TX, USA) utilizing the METAN and METBIAS
odules [16]. The effect of PUFA on the incidence of POAF was
resented as risk ratio (RR) with 95% conﬁdence intervals (CIs).
eterogeneity was evaluated with Cochran’s Q statistic and qual-
ty by I2 statistic. A value of p < 0.1 for Q test or I2 > 50% indicated
igniﬁcant between-study heterogeneity. If no heterogeneity was
resent, ﬁxed effect meta-analysis was performed to calculate RR.
lternatively, random effect meta-analysis was performed when
eterogeneity existed. Publication bias was evaluated by Begg’s
nd Egger’s method. Results were considered statistically signiﬁ-
ant if p < 0.05. Sensitivity analyses were undertaken by omitting
ne study at a time to examine inﬂuence of one study on the over-
ll summary estimate, and ﬁxed or random effect models described
bove were used.
We  explored possible explanations for heterogeneity according
o a prior hypothesis, which included differences in the base-
ine characteristics of patients, concurrent medications that might
nﬂuence the incidence of AF, types of cardiac surgery, the ratio
f eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA), and
he quality of studies. Speciﬁcally, we compared the results of
tudies grouped by the following factors: (1) mean age; (2) male
roportion; (3) mean left ventricular ejection fraction (≥55% vs
55%); (4) proportion of patients using beta-blockers, angiotensin-
onverting enzyme inhibitors, and statins; (5) types of cardiac
urgery (CABG only vs CABG and valve surgery); (6) concomitant
iseases, such as diabetes and hypertension; (7) EPA/DHA ratio
n the PUFA; and (8) Jadad score (>3 vs ≤3). Recognizing that
ny cut point is to some extent arbitrary, we chose cut points
efore analyzing the data using 2 criteria. First, thresholds had
o be biologically sensitive; and second, they had to divide the
rials into 2 subgroups with a more or less similar number of
rials.iology 63 (2014) 53–59
Results
Search  results
Our  preliminary search yielded 87 potential literature citations.
After the evaluation, a total of 79 articles were excluded for different
reasons. Eight trials with 2687 patients (1337 patients assigned to
PUFA group and 1350 patients assigned to the control arm) were
included in the analysis. Of the 8 studies, 5 [7,8,10,12,13] reported
that there was  no effect of PUFA on POAF after cardiac surgery,
and another 3 studies [6,9,11] showed that treatment with PUFA
preoperatively could reduce the incidence of POAF signiﬁcantly.
The characteristics of included studies are shown in Table 1.
Baseline  characteristics of patients and quality of the included
studies
The  baseline characteristics of patients enrolled are summarized
in Table 2. There was no signiﬁcant difference in the baseline char-
acteristics of patients between the two  groups. The mean age of
patients in individual trials ranged from 63.4 to 68 years. The pro-
portion of males was  75.9% and 74.2% in the PUFA and control
groups, respectively. Diabetes was present in 28.1% and 28.4% of
patients in the PUFA and control groups, respectively. Hypertension
was present in 75.2% and 72.4% of patients in the PUFA and control
groups, respectively. We  used the Jadad quality scale to evaluate
the quality of the included studies. There were 5 studies with Jadad
scores more than 3, and another 3 studies in our analysis had Jadad
scores less than or equal to 3 (Table 3).
Effect of PUFA on the incidence of post-operative atrial ﬁbrillation
Fig.  1 shows a forest plot comparing the incidence of POAF in
patients treated with PUFA to those who  did not receive PUFA.
I2 statistic and Q test showed that there was a signiﬁcant hetero-
geneity of treatment effect among the studies for POAF (I2 = 53.6%,
2 = 15.8, p = 0.035), so the random effect model was  used to pool
the data. Treatment with PUFA had no effect on the incidence of
POAF in patients undergoing cardiac surgery compared to placebo
[RR 0.856; 95% CI 0.707–1.036, p = 0.110; Fig. 1].
Sensitivity analyses
First,  sensitivity analyses were performed by omitting one study
at a time and calculating the pooled RR for the remaining studies.
This procedure was used to ensure that no individual study was
entirely responsible for the combined results. Second, the pooled RR
was estimated using ﬁxed effect model and random effect model,
respectively. Sensitivity analysis indicated that the results of the
meta-analysis were reliable and stable.
Subgroup analyses
Subgroup analyses were separately performed to investigate
heterogeneity. The results showed that concomitant diabetes, the
ratio of EPA/DHA in the PUFA, and the quality of the study might
impact the effect of PUFA on AF after open heart surgery (Table 4).
Risk of publication biasFunnel  plots were constructed to assess the risk of publication
bias. The Egger’s and Begg’s tests showed no potential publica-
tion bias existed among the included trials (Egger’s test: p = 0.298;
Begg’s test: p = 0.174; Fig. 2).
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Table  1
Characteristics and quality of enrolled studies.
Study No. of patients Include criteria Exclude criteria Treatment group Control group POAF diagnosis
criteria
Calo (2005) 160 Age >18 years; sinus
rhythm  and stable
hemodynamic
conditions
Valvular  surgery;
history  of SVA or
Class  I/III
antiarrhythmic
medications
Two  capsules/day
PUFA ﬁve days before
surgery  and continued
until  discharge
Usual  care Duration >5 min or
requiring
intervention
Farquharson (2011) 194 Age >18 years; CABG
and/or  valve repair or
replacement
History  of AF/af or
Class  I/III
antiarrhythmic
medications;
urgent surgery;
heart
failure(NYHA4); MI
within2  weeks
15  ml/day ﬁsh oil for 3
weeks before surgery
and  continued 6 days
after  surgery or until
discharge
Sunﬂower  oil Duration ≥10 min
or requiring
intervention
Heidarsdottir  (2010) 168 Scheduled for elective
or  urgent open heart
surgery;  age≥40years
History of SVA or
Class  I/III
anti-arrhythmic
medications;
emergent
operation
PUFA  initiated 5–7
days  before surgery
and  continued to
discharge  but no longer
than  2weeks after the
surgery
2  g/d olive oil Duration >5 min
Heidt (2009) 102 Age >18 years; sinus
rhythm  and stable
hemodynamic
conditions; freedom
from  angina
Concomitant valve
surgery;  history of
SVA  or
anti-arrhythmic
therapy
100  mg/kg/d 100 mg/kg/d soya
oil
Duration >15 min
Mozaffarian (2012) 1516 Age >18 years;
scheduled for cardiac
surgery;  sinus rhythm
Absence of sinus
rhythm;  regular
use  of ﬁsh oil;
known  allergy or
intolerance  to ﬁsh
oil  or olive oil;
pregnant; existing
or  planned cardiac
transplant  or use of
ventricular  assist
device
10-g  preoperative
loading dose over 5
days  followed by 2 g/d
postoperatively
Olive oil Arrhythmias of at
least  30 s duration
Sandesara (2012) 243 18–85 years old;
undergoing elective
CABG  with or without
concomitant  valve
surgery
Emergency  CABG;
unstable  angina;
heart  failure;
persistent AF or AF
at  the time of
screening; planned
surgery  of AF;
usage  of Class I/III
antiarrythmic
drug;  patients with
PM  or ICD;
pregnancy; usage
of  PUFA at the time
of  screening
4  g/d PUFA before
surgery and 2 g/d after
surgery until the
primary  end point or
14days
A  matching corn oil
placebo
Any  episode of AF
or  ﬂutter requiring
intervention
Saravanan  (2010) 103 Age >18 years; undergo
elective  CABG
History of AF or
Class  I/III
antiarrythmic drug
2 g/d n-3 PUFA 2 g/d olive oil Duration >30 s
Sorice (2011) 201 Age >18 years; sinus
rhythm  and stable
hemodynamic
conditions
History  of AF or
Class  I/III
antiarrythmic
drug; severe
valvular disease
850–882 mg PUFA
initiated 5–7 days
before  surgery and
continued  to discharge
NA Duration >5 min or
requiring
intervention
P atril ﬁ
v ion; P
D
d
o
g
t
m
i
i
pOAF, post-operative atrial ﬁbrillation; CABG, coronary artery bypass grafting; AF, 
entricular arrhythmias; MI,  myocardial infarction; NYHA, New York heart associat
iscussion
AF is the most common complication encountered after car-
iac surgery. The incidence of POAF has increased continuously
ver the past decades with the aging of the population under-
oing cardiac surgery. The underlying mechanisms involved in
he development of POAF are multifactorial and are for the
oment far from being fully elucidated. But there is an increas-
ng body of evidence that inﬂammation and oxidative stress play
mportant roles in the pathogenesis of POAF [17]. Resolvin and
rotectin, bioactive mediators in the process of the metabolismbrillation; PM,  pacemaker; ICD, implantable cardioverter deﬁbrillator; SVA, super-
UFA, polyunsaturated fatty acids; NA, not available.
of  PUFA in the cells, showed anti-inﬂammatory effects and
prompted the resolution of inﬂammation [18]. A meta-analysis
found that dietary PUFA was associated with plasma inﬂam-
matory biomarker levels, reﬂecting lower level of inﬂammation
in cardiovascular diseases [19]. Some experiments and trials
also showed the antioxidant effect of PUFA [20,21]. In addi-
tion, PUFA had an antiarrhythmic effect through direct steric
interference with sodium, potassium, and calcium channels in
the cardiac myocyte membrane [22]. Therefore, PUFA may  have
an effect on preventing POAF in patients undergoing cardiac
surgery.
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The previous meta-analyses showed that administration
with PUFA preoperatively had no effect on the incidence of
POAF in patients undergoing open heart surgery [14,23,24]. But
there were fewer RCTs enrolled in the meta-analyses. Since then,
the results of 4 RCTs with a large number of patients have been
published. We  performed this meta-analysis of 8 RCTs with 2687
patients to evaluate the effect of PUFA on the incidence of AF in
patients undergoing cardiac surgery. Our result showed that treat-
ment with PUFA preoperatively failed to reduce the incidence of
POAF.
Considering the signiﬁcant heterogeneity existing in this pooled
analysis, we performed subgroup analyses to better understand
the association in different subgroups. The results indicated that
patients with diabetes appeared to be likely to get beneﬁts from
PUFA therapy preoperatively. However, several factors might inﬂu-
ence the potential beneﬁts of PUFA supplementation on POAF.
First,  patients from different areas may  have different responses
to the supplementation with PUFA. The diet in Iceland is mainly
composed of seal and whale which is extremely rich in marine
PUFA. So the people from Iceland, including patients enrolled
by Heidarsdottir et al. [8], might have a higher baseline level of
serum PUFA. Some experiments showed there was a low thresh-
old for the incorporation of PUFA into the cell membrane [25].
Therefore, the daily diet may  have resulted in the patients from
Iceland having a higher baseline level of PUFA, which passed
the threshold for the incorporation of PUFA into the cell mem-
brane. This could explain the result that there was no effect of
the administration with PUFA in patients enrolled by Heidarsdottir
et al. [8].
In  addition, different types of surgery and difference between
surgical procedures would also inﬂuence the incidence of POAF
and the effect of PUFA treatment. For example, there were some
approaches for mitral valve surgery and some differing incisions
on the atrium. The design of atrial incision may  be related to the
incidence of POAF. A multicenter Vererans Affairs study found
that the surgery type would inﬂuence the incidence of POAF and
the patients undergoing valve surgery had a higher rate of POAF
than the patients with CABG [26]. In the study by Sorice et al.
[11], the researchers found that administration of PUFA signif-
icantly reduced the incidence of POAF in patients undergoing
“on-pump” CABG surgery. However, PUFA had no effect in the
patients with “off-pump” surgery. In the study by Farquharson et al.,
the researchers found a trend toward a greater decrease in AF with
PUFA in patients undergoing valve surgery compared to those with
CABG only [7]. In our subgroup analyses, we failed to demonstrate
that different types of surgery would inﬂuence the effect of PUFA
on the incidence of POAF. However, we just divided the trials into
CABG-only group and CABG + valve surgery group. The proportion
of valve surgery and the components of the CABG were not consid-
ered.
Among the trials included in this meta-analysis, there was a sig-
niﬁcant difference in the diagnostic criteria of POAF. In the trial
by Saravanan et al. [10], the diagnostic criterion of POAF was an
episode of AF > 30 s. In the trial by Heidt et al. [9], the criterion
was an episode of AF for longer than 15 min. In the study by Far-
quharson et al. [7], the diagnostic criterion of POAF was  episode
of AF duration ≥10 min  or requiring intervention. So the different
diagnostic criteria of POAF would change the rate of POAF and inﬂu-
ence the potential beneﬁts of administration with PUFA in patients
undergoing cardiac surgery.
The favorable effect of PUFA on POAF was originally attributed to
EPA. However, there is more DHA than EPA accumulated in the body
and DHA has broadly similar biologic effects. Some trials suggested
that there were some differential properties between EPA and DHA
[27]. Some experiments showed that DHA, at lower concentration
than EPA, could block the ion channels in the myocyte, some of
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Table  3
Jadad  score of the trials enrolled in this meta-analysis.
Study Randomization Double blinding Withdrawals and dropouts Jadad score
Calo (2005) The method of randomization was
based on computer-generated
randomization list
No-blind A description of
withdrawals  and dropouts
3
Farquharson (2011) The method of randomization was
based on computer-generated
randomization list using blocks of
20
The method of double blinding was
described and it was appropriate
A description of
withdrawals  and dropouts
5
Heidarsdottir (2010) The study was described as
randomized
The method of double blinding was
described and it was appropriate
A description of
withdrawals  and dropouts
4
Heidt (2009) The study was described as
randomized
The method of double blinding was
described and it was appropriate
Not describe the follow-up 3
Mozaffarian  (2012) The method of randomization was
by means of computer-generated
numbers
The  method of double blinding was
described and it was appropriate
A description of
withdrawals  and dropouts
5
Sandesara (2012) The study was described as
randomized
The method of double blinding was
described and it was appropriate
A description of
withdrawals  and dropouts
4
Saravanan (2010) Random assignment was  based on
a computer-generated
randomization list obtained using
blocks of size 4
The method of double blinding was
described and it was appropriate
A description of
withdrawals  and dropouts
5
Sorice (2011) The study was described as No-blind A description of 2
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hich were present only in atrial cells [28]. The ratios of EPA and
HA were different among the trials enrolled in our meta-analysis.
PA/DHA in the trial by Calo et al. was 1/2 [6], but the ratio was 1.2/1
n the trial by Saravanan et al. [10]. Our results of subgroup analy-
es showed that the ratio of EPA/DHA < 1 in the PUFA might have
 good effect on the incidence of AF after cardiac surgery. How-
ver, the quality of trials in the group of EPA/DHA < 1 was lower
han in the group of EPA/DHA > 1. The subgroup analyses also indi-
ated that the quality of the trials would inﬂuence the results of the
eta-analysis.
The present meta-analysis has several features that distinguish
t from the similar meta-analyses that were published. First, we
ncluded 4 additional randomized controlled trials, and the number
f patients in our meta-analysis is far larger than that in the previ-
us meta-analyses. Second, our meta-analysis showed that patients
ith diabetes might get beneﬁts from treatment with PUFA pre-
peratively. A retrospective cohort study found that patients with
Fig. 1. Forest plot of risk ratio (RR) for treatment with polyunsaturated fatty acids onwithdrawals  and dropouts
diabetes had worse prognosis than patients without diabetes who
underwent cardiac surgery [29]. Therefore, this result may  be
important for patients in this sub-group.
Study limitations
There are limitations of the present study. Lack of patient-
speciﬁc data and the inclusion of trials of varying quality and design
are limitations common to all meta-analyses. However, to at least
partly nullify the latter factors, we  included only randomized con-
trolled trials. In addition, the appropriate dose of PUFA and the
appropriate ratio of EPA and DHA remain uncertain. Further, the
diagnostic criterion of POAF was  arbitrary in the studies included
in this analysis. However, the deﬁnition of AF episodes was shown
in the 2012 Heart Rhythm Society/European Heart Rhythm Asso-
ciation/European Cardiac Arrhythmia Society Expert Consensus
Statement on catheter and surgical ablation of AF. In this statement,
 the incidence of atrial ﬁbrillation after cardiac surgery. CI, conﬁdence interval.
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Table 4
Results of sub-group analyses.
Subgroup Studies (N) RR (95% CI) p-Value
Age (years)
≤65 4  0.86(0.70–1.06) 0.149
>65  4 0.82(0.53–1.27) 0.377
Male  proportion
≤80% 4 0.921(0.793–1.068) 0.275
>80%  4 0.762(0.473–1.229) 0.265
LVEF
≤55%  3 0.704(0.468–1.058) 0.092
>55%  5 0.911(0.732–1.133) 0.400
Type  of surgery
CABG  only 4 0.666(0.369–1.202) 0.177
CABG+  valve 4 0.945(0.840–1.063) 0.342
Therapy  with statin
≤70% 3  0.647(0.364–1.1.49) 0.137
>70% 3 0.955(0.709–1.286) 0.763
Therapy  with -blocker
≤70%  4 0.713(0.507–1.004) 0.053
>70%  3 1.041(0.857–1.265) 0.683
Therapy  with ACEI
≤70%  4 0.859(0.699–1.056) 0.149
>70%  3 0.787(0.274–2.255) 0.655
Jadad  score
≤3 3 0.502(0.343–0.734) <0.001
>3 5 0.969(0.863–1.088) 0.590
Diabetes
≤30%  3 1.099(0.888–1.145) 0.895
>30%  4 0.693(0.511–0.939) 0.018
Hypertension
≤70%  3 0.935(0.612–1.429) 0.757
>70%  4 0.825(0.646–1.055) 0.125
EPA/DHA
≤1  2 0.476(0.305–0.743) 0.001
>1  5 0.969(0.863–1.088) 0.590
R G, cor
e
a
t
r
a
F
dR, risk ratio; CI, conﬁdence intervals; LVEF, left ventricular ejection fraction; CAB
icosapentaenoic acid; DHA, docosahexaenoic acid.
ny arrhythmia that had the electrocardiographic (ECG) charac-
eristics of AF and lasted sufﬁciently long for a 12-lead ECG to be
ecorded, or at least 30 s on a rhythm strip, should be considered
n AF episode [30]. Further study with this new deﬁnition of AF
ig. 2. Begg’s funnel plot with pseudo 95% conﬁdence intervals to assess for evi-
ence of publication bias.onary artery bypass grafting; ACEI, angiotensin converting enzyme inhibitor; EPA,
episodes, and the optimal dose and composition of PUFA is needed
to identify the effect of PUFA on POAF.
Conclusion
The present analysis suggests that treatment with PUFA pre-
operatively had no effect on the incidence of POAF in patients
undergoing open heart surgery. However, patients with diabetes
might beneﬁt from treatment with PUFA preoperatively.
Disclosure
There are no conﬂicts of interests to disclose.
Acknowledgement
We thank Professor Heidt for the free full text of his article.
References[1] Mathew JP, Parks R, Savino JS, Friedman AS, Koch C, Mangano DT, Browner
WS.  Atrial ﬁbrillation following coronary artery bypass graft surgery: predic-
tors,  outcomes, and resource utilization. MultiCenter Study of Perioperative
Ischemia Research Group. JAMA 1996;276:300–6.
f Card
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
Haines  DE, Haissaguerre M,  et al. 2012 HRS/EHRA/ECAS Expert ConsensusB. Zhang et al. / Journal o
[2] Mariscalco G, Klersy C, Zanobin M,  Banach M,  Ferrarese S, Borsani P, Cantore C,
Biglioli  P, Sala A. Atrial ﬁbrillation after isolated coronary surgery affects late
survival.  Circulation 2008;118:1612–8.
[3] Kaireviciute D, Aidietis A, Lip GY. Atrial ﬁbrillation following cardiac surgery:
clinical  features and preventative strategies. Eur Heart J 2009;30:410–25.
[4] Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects
on  risk factors, molecular pathways, and clinical events. J Am Coll Cardiol
2011;58:2047–67.
[5]  Sakabe M,  Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK,
Nattel  S. Omega-3 polyunsaturated fatty acids prevent atrial ﬁbrillation asso-
ciated  with heart failure but not atrial tachycardia remodeling. Circulation
2007;116:2101–9.
[6]  Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML,  de Ruvo E, Meo  A,
Pandozi  C, Staibano M,  Santini M.  N-3 fatty acids for the prevention of atrial
ﬁbrillation  after coronary artery bypass surgery—a randomized, controlled
trial.  J Am Coll Cardiol 2005;45:1723–8.
[7] Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA, Cleland
LG,  Sullivan TR, James MJ,  Young GD. Effect of dietary ﬁsh oil on atrial ﬁbrillation
after  cardiac surgery. Am J Cardiol 2011;108:851–6.
[8]  Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V,
Gottskalksson G, Palsson R, Indridason OS. Does treatment with n-3 polyunsat-
urated  fatty acids prevent atrial ﬁbrillation after open heart surgery? Europace
2010;12:356–63.
[9]  Heidt MC,  Vician M,  Stracke SK, Stadlbauer T, Grebe MT, Boening A, Vogt PR,
Erdogan  A. Beneﬁcial effects of intravenously administered N-3 fatty acids
for  the prevention of atrial ﬁbrillation after coronary artery bypass surgery:
a  prospective randomized study. Thorac Cardiovasc Surg 2009;57:276–80.
10] Saravanan P, Bridgewater B, West AL, O’Neill SC, Calder PC, Davidson NC.
Omega-3  fatty acid supplementation does not reduce risk of atrial ﬁbrillation
after  coronary artery bypass surgery: a randomized, double-blind, placebo-
controlled  clinical trial. Circ Arrhythm Electrophysiol 2010;3:46–53.
11] Sorice M,  Tritto FP, Sordelli C, Gregorio R, Piazza L. N-3 polyunsaturated fatty
acids  reduces post-operative atrial ﬁbrillation incidence in patients undergo-
ing  “on-pump” coronary artery bypass graft surgery. Monaldi Arch Chest Dis
2011;76:93–8.
12] Mozaffarian D, Marchioli R, Macchia A, Silletta MG,  Ferrazzi P, Gardner TJ, Latini
R,  Libby P, Lombardi F, O’Gara PT, Page RL, Tavazzi L, Tognoni G, OPERA Inves-
tigators.  Fish oil and postoperative atrial ﬁbrillation: the Omega-3 Fatty Acids
for  Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.
JAMA  2012;308:2001–11.
13] Sandesara CM,  Chung MK,  Van Wagoner DR, Barringer TA, Allen K, Ismail HM,
Zimmerman  B, Olshansky B. A randomized, placebo-controlled trial of omega-3
fatty  acids for inhibition of supraventricular arrhythmias after cardiac surgery:
the  FISH Trial. J Am Heart Assoc 2012;1:e000547.
14]  Armaganijan L, Lopes RD, Healey JS, Piccini JP, Nair GM,  Morillo CA. Do omega-3
fatty  acids prevent atrial ﬁbrillation after open heart surgery? A meta-analysis
of  randomized controlled trials. Clinics (Sao Paulo) 2011;66:1923–8.
15] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay
HJ.  Assessing the quality of reports of randomized clinical trials: is blinding
necessary?  Control Clin Trials 1996;17:1–12.
16]  Chen X, Zhang N, Cai Y, Shi J. Evaluation of left ventricular diastolic function
using  tissue Doppler echocardiography and conventional doppler echocar-
diography  in patients with subclinical hypothyroidism aged <60 years: a
meta-analysis.  J Cardiol 2013;61:8–15.iology 63 (2014) 53–59 59
17] Echahidi N, Pibarot P, O’Hara G, Mathieu P. Mechanisms, prevention, and
treatment  of atrial ﬁbrillation after cardiac surgery. J Am Coll Cardiol
2008;51:793–801.
18]  Weylandt KH, Chiu CY, Gomolka B, Waechter SF, Wiedenmann B. Omega-3
fatty  acids and their lipid mediators: towards an understanding of resolvin and
protectin  formation. Prostaglandins Other Lipid Mediat 2012;97:73–82.
19] Rangel-Huerta OD, Aguilera CM, Mesa MD,  Gil A. Omega-3 long-chain
polyunsaturated fatty acids supplementation on inﬂammatory biomakers: a
systematic  review of randomised clinical trials. Br J Nutr 2012;107(Suppl.
2):S159–70.
20]  Xie NL, Zhang W,  Li J, Liang H, Zhou H, Duan W,  Xu X, Yu S, Zhang H, Yi D.
Alpha-linolenic acid intake attenuates myocardial ischemia/reperfusion injury
through  anti-inﬂammatory and anti-oxidative stress effects in diabetic but not
normal rats. Arch Med  Res 2011;42:171–81.
21] Takaki A, Umemoto S, Ono K, Seki K, Ryoke T, Fujii A, Itagaki T, Harada M,  Tanaka
M,  Yonezawa T, Ogawa H, Matsuzaki M,  ELIA study group. Add-on therapy of
EPA  reduces oxidative stress and inhibits the progression of aortic stiffness
in  patients with coronary artery disease and statin therapy: a randomized
controlled study. J Atheroscler Thromb 2011;18:857–66.
22]  Richardson ES, Iaizzo PA, Xiao YF. Electrophysiological mechanisms of the
anti-arrhythmic  effects of omega-3 fatty acids. J Cardiovasc Transl Res
2011;4:42–52.
23]  Benedetto U, Angeloni E, Melina G, Danesi TH, Di Bartolomeo R, Lechiancole A,
Reﬁce  S, Roscitano A, Comito C, Sinatra R. n-3 polyunsaturated fatty acids for the
prevention  of postoperative atrial ﬁbrillation: a meta-analysis of randomized
controlled  trials. J Cardiovasc Med  (Hagerstown) 2013;14:104–9.
24] Takagi H, Umemoto T. Preoperative n-3 polyunsatured fatty acids do not
reduce  postoperative atrial ﬁbrillation in cardiac surgery. Angiology 2011;62:
276–7.
25]  Venkatraman J, Toohey T, Clandinin M.  Does a threshold for the effect of dietary
omega-3  fatty acids on the fatty acid composition of nuclear envelope phos-
pholipids  exist? Lipids 1992;27:94–7.
26] Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson WG,
Tarazi  R, Shroyer AL, Sethi GK, Grover FL, Hammermeister KE. Atrial ﬁbrillation
after  cardiac surgery: a major morbid event? Ann Surg 1997;226:501–11.
27] De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med
2011;364:2439–50.
28]  Li GR, Sun HY, Zhang XH, Cheng LC, Chiu SW,  Tse HF, Lau CP. Omega-3
polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed
rectiﬁer  K + currents and Na + current in human atrial myocytes. Cardiovasc Res
2009;81:286–93.
29] Minakata K, Bando K, Takanashi S, Konishi H, Miyamoto Y, Ueshima K, Sato
T,  Ueda Y, Okita Y, Masuda I, Okabayashi H, Yaku H, Yasuno S, Muranaka
H,  Kasahara M,  et al. Impact of diabetes mellitus on outcomes in Japanese
patients  undergoing coronary artery bypass grafting. J Cardiol 2012;59:
275–84.
30]  Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Dami-
ano  Jr RJ, Davies DW,  DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD,Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommen-
dations  for patient selection, procedural techniques, patient management and
follow-up, deﬁnitions, endpoints, and research trial design. Europace 2012;14:
528–606.
